[{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"87a89c62-067c-468b-af11-fef3c384939e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530552","created_at":"2024-02-13T21:25:45.706Z","updated_at":"2025-02-25T17:36:44.962Z","phase":"Phase 2","brief_title":"Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland","source_id_and_acronym":"NCT04530552","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • NCAM1","pipe":" | ","alterations":" NCAM1 positive","tags":["CD8 • CD4 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 11/06/2024","primary_completion_date":" 11/06/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-01-29"},{"id":"34637cf2-d41a-41b6-a1f9-4f46ac1afd16","acronym":"","url":"https://clinicaltrials.gov/study/NCT03436654","created_at":"2021-01-19T15:34:33.162Z","updated_at":"2024-07-02T16:34:27.070Z","phase":"Phase 2","brief_title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","source_id_and_acronym":"NCT03436654","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 02/14/2025","primary_completion_date":" 02/14/2025","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2024-06-11"},{"id":"2abe92f5-a7aa-49ec-831a-73b25aaf9f65","acronym":"TRAMP","url":"https://clinicaltrials.gov/study/NCT05960578","created_at":"2024-01-11T23:19:44.824Z","updated_at":"2024-07-02T16:34:36.939Z","phase":"Phase 2","brief_title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","source_id_and_acronym":"NCT05960578 - TRAMP","lead_sponsor":"University of Washington","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-10"},{"id":"d79bfdb8-ad5a-46da-91a6-a2f9ca67b203","acronym":"DynaMO","url":"https://clinicaltrials.gov/study/NCT02703623","created_at":"2021-01-18T13:12:02.865Z","updated_at":"2024-07-02T16:35:03.313Z","phase":"Phase 2","brief_title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02703623 - DynaMO","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 05/18/2016","start_date":" 05/18/2016","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-16"},{"id":"ee1f7ecf-9bc4-4111-8b8a-fd3789290137","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926181","created_at":"2021-06-15T17:53:11.788Z","updated_at":"2024-07-02T16:35:07.351Z","phase":"Phase 2","brief_title":"Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04926181","lead_sponsor":"Rahul Aggarwal","biomarkers":" RB1 • SYP","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-04-26"},{"id":"1144c5d4-f73f-4a5b-a392-3076fd5a3adf","acronym":"INNOVATE","url":"https://clinicaltrials.gov/study/NCT04134260","created_at":"2021-01-18T20:11:49.250Z","updated_at":"2024-07-02T16:35:20.295Z","phase":"Phase 3","brief_title":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer","source_id_and_acronym":"NCT04134260 - INNOVATE","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 586","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-02-07"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"e61a842e-3393-4ae3-9685-c52db2616f42","acronym":"4CAST","url":"https://clinicaltrials.gov/study/NCT04947189","created_at":"2021-07-01T14:54:41.667Z","updated_at":"2024-07-02T16:35:33.448Z","phase":"Phase 1b","brief_title":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04947189 - 4CAST","lead_sponsor":"St Vincent's Hospital, Sydney","biomarkers":" HER-2 • PGR • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • EGFR positive","tags":["HER-2 • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • dexamethasone • seviteronel (INO-464)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-16"},{"id":"a649e038-73a2-47ce-9947-ff0d7e645f60","acronym":"CHAMPION","url":"https://clinicaltrials.gov/study/NCT05717582","created_at":"2023-02-08T18:00:34.299Z","updated_at":"2024-07-02T16:35:56.149Z","phase":"Phase 2","brief_title":"Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment","source_id_and_acronym":"NCT05717582 - CHAMPION","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-02-08"},{"id":"2b5e323f-9e4a-4d5e-924a-a741c944cff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990209","created_at":"2021-07-13T22:53:46.156Z","updated_at":"2025-02-25T14:56:51.373Z","phase":"Phase 2","brief_title":"Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)","source_id_and_acronym":"NCT01990209","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" PGR","pipe":" | ","alterations":" AR expression","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e orteronel (TAK 700)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-06-30"},{"id":"5edcf750-2efe-4fff-8613-fe4db76a5f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02770391","created_at":"2021-01-20T21:52:08.137Z","updated_at":"2024-07-02T16:36:08.521Z","phase":"Phase 2","brief_title":"Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer","source_id_and_acronym":"NCT02770391","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMPRSS2 • HSD3B1 • FKBP5 • UBE2C","pipe":"","alterations":" ","tags":["TMPRSS2 • HSD3B1 • FKBP5 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 04/29/2020","study_completion_date":" 04/29/2020","last_update_posted":"2022-06-21"},{"id":"76d00842-33fa-4faa-bc62-878fb551c3f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02849990","created_at":"2021-01-18T13:59:26.821Z","updated_at":"2024-07-02T16:36:18.475Z","phase":"Phase 2","brief_title":"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy","source_id_and_acronym":"NCT02849990","lead_sponsor":"University of Washington","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 12/10/2018","primary_completion_date":" 12/10/2018","study_txt":" Completion: 12/10/2020","study_completion_date":" 12/10/2020","last_update_posted":"2022-01-13"},{"id":"12afa15f-7965-45d2-ae3a-ebcbd432c421","acronym":"","url":"https://clinicaltrials.gov/study/NCT04103853","created_at":"2021-01-18T20:04:18.339Z","updated_at":"2024-07-02T16:36:24.021Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT04103853","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pruxelutamide (GT0918)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-09-24"},{"id":"585a32f3-28c6-4f08-90c9-99a6438a2ce5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02987829","created_at":"2021-04-24T03:55:23.010Z","updated_at":"2024-07-02T16:36:31.325Z","phase":"Phase 1/2","brief_title":"Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients","source_id_and_acronym":"NCT02987829","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TRC253"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 10/06/2019","primary_completion_date":" 10/06/2019","study_txt":" Completion: 11/09/2020","study_completion_date":" 11/09/2020","last_update_posted":"2021-04-23"},{"id":"c9290568-594d-4db4-8dee-d6569ecbe250","acronym":"ARNEO","url":"https://clinicaltrials.gov/study/NCT03080116","created_at":"2021-01-18T15:10:23.112Z","updated_at":"2024-07-02T16:36:36.870Z","phase":"Phase 2","brief_title":"Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy","source_id_and_acronym":"NCT03080116 - ARNEO","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" PTEN • FOLH1 • SPOP","pipe":" | ","alterations":" FOLH1 expression","tags":["PTEN • FOLH1 • SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-12-24"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"044ad04e-9242-4d5c-b71d-62ab6ac33aad","acronym":"STEM","url":"https://clinicaltrials.gov/study/NCT02970682","created_at":"2021-01-18T14:36:07.066Z","updated_at":"2024-07-02T16:36:58.181Z","phase":"Phase 2","brief_title":"SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer","source_id_and_acronym":"NCT02970682 - STEM","lead_sponsor":"Evgen Pharma","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • Sulforadex (sulforafan alfadex)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-07-12"},{"id":"74bb0dc5-6670-4a97-bed0-b1c45b0dfe37","acronym":"CLARITY-01","url":"https://clinicaltrials.gov/study/NCT02580448","created_at":"2021-01-18T12:30:49.015Z","updated_at":"2024-07-02T16:37:03.253Z","phase":"Phase 1/2","brief_title":"CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)","source_id_and_acronym":"NCT02580448 - CLARITY-01","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-01"},{"id":"25170b14-2ea2-49b0-acfc-f00d60de235f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02130700","created_at":"2021-01-18T09:53:00.309Z","updated_at":"2024-07-02T16:37:10.952Z","phase":"Phase 2","brief_title":"Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer","source_id_and_acronym":"NCT02130700","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-05-07"},{"id":"7f44dec8-1a44-4b9d-ac82-d895aae03fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02144051","created_at":"2021-01-18T09:57:38.493Z","updated_at":"2024-07-02T16:37:30.569Z","phase":"Phase 1","brief_title":"Phase I Open Label Dose Escalation Study to Investigate the Safety \u0026 Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors","source_id_and_acronym":"NCT02144051","lead_sponsor":"AstraZeneca","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IONIS-AR-2.5Rx"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2016-07-14"}]